Roivant Sciences’ $200 Million Common Shares Offering

Davis Polk & Wardwell and Conyers Dill & Pearman advised Roivant Sciences Ltd. on the offering. Cooley advised Immunovant on the transaction.Roivant Sciences Ltd. (Nasdaq:ROIV) announced a…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Leila Ahmed

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here